Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

orifarm generics a/s - ibuprofen; pseudoefedrinhydroklorid - filmdragerad tablett - 200 mg/30 mg - pseudoefedrinhydroklorid 30 mg aktiv substans; ibuprofen 200 mg aktiv substans

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

mylan hospital as - eptifibatid - infusionsvätska, lösning - 0,75 mg/ml - eptifibatid 0,75 mg aktiv substans - eptifibatid

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

mylan hospital as - eptifibatid - injektionsvätska, lösning - 2 mg/ml - eptifibatid 2 mg aktiv substans - eptifibatid

Европска Унија - Шведски - EMA (European Medicines Agency)

bayer ag - iloprost - hypertoni, lungformig - antitrombotiska medel - behandling av patienter med primär pulmonell hypertension, klassificerad som new york heart association funktionsklass iii, för att förbättra träningskapacitet och symtom.

Европска Унија - Шведски - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, squamous cell - antineoplastiska medel - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

zentiva k.s. - iloprosttrometamol - lösning för nebulisator - 20 mikrogram/ml - etanol, vattenfri hjälpämne; iloprosttrometamol 26,7 mikrog aktiv substans

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

zentiva k.s. - iloprosttrometamol - lösning för nebulisator - 10 mikrogram/ml - iloprosttrometamol 13,4 mikrog aktiv substans; etanol, vattenfri hjälpämne

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

ebb medical ab - fenylefrinhydroklorid - injektionsvätska, lösning - 0,1 mg/ml - fenylefrinhydroklorid 0,122 mg aktiv substans - fenylefrin

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - rosuvastatinkalcium - filmdragerad tablett - 10 mg - rosuvastatinkalcium 10,4 mg aktiv substans; laktosmonohydrat hjälpämne - rosuvastatin

Шведска - Шведски - Läkemedelsverket (Medical Products Agency)

stada arzneimittel ag - rosuvastatinkalcium - filmdragerad tablett - 20 mg - rosuvastatinkalcium 20,79 mg aktiv substans; laktosmonohydrat hjälpämne - rosuvastatin